OSCR logo

Oscar Health, Inc. Stock Price

NYSE:OSCR Community·US$8.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 184 Fair Values set on narratives written by author

OSCR Share Price Performance

US$28.19
13.52 (92.16%)
US$45.34
Fair Value
US$28.19
13.52 (92.16%)
37.8% undervalued intrinsic discount
US$45.34
Fair Value
Price US$28.19
qnsg US$45.34
AnalystConsensusTarget US$22.60
AnalystHighTarget US$34.47

OSCR Community Narratives

Fair Value
·
Fair Value US$45.34 37.8% undervalued intrinsic discount

Oscar Health will leverage AI technology for future growth and revenue streams

0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
·
Fair Value US$24.2 16.5% overvalued intrinsic discount

Analysts Raise Oscar Health Price Target amid Profitability Hopes and New Healthcare Initiatives

2users have liked this narrative
0users have commented on this narrative
110users have followed this narrative
·
Fair Value US$34.47 18.2% undervalued intrinsic discount

Telemedicine, AI, And Demographics Will Forge A New Insurance Era

1users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
US$13
116.8% overvalued intrinsic discount
Profit Margin
4.3%
Future PE
7.22x
Price in 2029
US$15.93
US$34.47
18.2% undervalued intrinsic discount
Profit Margin
4.22%
Future PE
14.46x
Price in 2029
US$42.25

Trending Discussion

No trending discussion available.

Updated Narratives

OSCR logo

Oscar Health will leverage AI technology for future growth and revenue streams

Fair Value: US$45.34 37.8% undervalued intrinsic discount
14 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
OSCR logo

OSCR: ACA Exchange Risk Adjustment Tailwind Will Not Offset Margin Concerns

Fair Value: US$24.2 16.5% overvalued intrinsic discount
110 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
OSCR logo

OSCR: ACA Risk Adjustment Tailwinds Will Confront Ongoing Margin Execution Concerns

Fair Value: US$13 116.8% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with excellent balance sheet.

2 Risks
2 Rewards

Oscar Health, Inc. Key Details

US$13.3b

Revenue

US$11.0b

Cost of Revenue

US$2.3b

Gross Profit

US$2.4b

Other Expenses

-US$39.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
-0.13
17.39%
-0.30%
25.8%
View Full Analysis

About OSCR

Founded
2012
Employees
2305
CEO
Mark Bertolini
WebsiteView website
www.hioscar.com

Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

Recent OSCR News & Updates

Narrative Update Jul 25

OSCR: ACA Exchange Risk Adjustment Tailwind Will Not Offset Margin Concerns

Analysts have lifted the implied fair value estimate for Oscar Health from $22.60 to $24.20, citing more supportive views on the 2025 healthcare exchange risk adjustment true up and the company’s focused exposure to the individual ACA market, even as margin expectations remain measured and the future P/E assumption edges up toward 11x. Analyst Commentary Recent research on Oscar Health centers on how the individual Affordable Care Act market, risk adjustment outcomes, and margin trajectory could feed into valuation over the next few years.
Seeking Alpha Jul 22

Oscar Health: Strong Numbers Forced Re-Rating, Now Pay Attention To Continuous Execution

Summary Oscar Health has rerated to the $30 range, reflecting its strong performance but reduced asymmetry versus prior opportunities. Risk Adjustment Transfer dynamics and plan mix will pressure EPS and margins in Q2 and beyond, despite an encouraging Q1 medical loss ratio. I expect MLR to rise to the mid-to-high seventies and negative EPS for upcoming quarters, with SG&A likely flat as tech efficiencies are offset. I assign OSCR a Buy rating with a $37 target, reflecting a 15x P/E on probability-weighted $2.45 EPS, but urge a more cautious, execution-focused approach. Read the full article on Seeking Alpha

Recent updates

No updates